한글목차

유육종증 치료제 시장 규모는 최근 현저한 성장을 이루고 있습니다. 2025년 78억 8,000만 달러에서 2026년에는 84억 2,000만 달러에 이르고, CAGR 6.8%로 성장할 전망입니다. 지난 몇 년간 성장 요인으로는 유전체 연구의 발전, 시퀀싱 비용의 하락, 학술 연구의 확대, 진단 검사 증가, 제약 분야의 R&D 투자 증가 등을 꼽을 수 있습니다.

유육종증 치료제 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 109억 8,000만 달러에 이르고, CAGR은 6.9%를 나타낼 전망입니다. 예측 기간의 성장 요인으로는 개인 맞춤형 의료 도입, 동반진단 확대, AI를 활용한 유전체학, 제약사 수요 증가, 정부 주도의 유전체학 정책 등을 꼽을 수 있습니다. 예측 기간의 주요 동향으로는 정밀의료의 적용 확대, cfDNA 및 액체 생검의 사용 증가, 고처리량 유전자 타이핑 기술, AI 기반 데이터 분석과의 통합, 약리유전체학의 성장 등을 들 수 있습니다.

임상시험 건수 증가는 향후 몇 년 동안 유육종증 치료제 시장의 성장을 견인할 것으로 예측됩니다. 임상시험은 의료 시술이나 개입의 안전성, 유효성, 잠재적 부작용을 평가하기 위해 인간을 대상으로 하는 연구입니다. 임상시험 증가는 주로 개인 맞춤형 의료 및 혁신적 치료법에 대한 수요 증가에 기인하며, 이는 안전성과 유효성을 보장하기 위해 철저한 시험이 필요합니다. 유육종증 치료제는 질병 진행에 미치는 영향, 안전성 프로파일, 치료 결과를 평가하는 이러한 시험을 통해 보다 효과적인 치료법을 찾아내는 것을 목표로 하고 있습니다. 예를 들어, 2024년 12월 영국 제약업계 단체인 영국제약산업협회(ABPI)가 발표한 바에 따르면, 영국에서 시작된 업계 주도 임상시험의 총 수는 2022년 411건에서 2023년 426건으로 증가하였습니다. 또한, 같은 기간 동안 임상 3상 시험 개시 건수는 182건에서 212건으로 16.5% 증가했습니다. 따라서 임상시험 증가는 유육종증 치료제 시장의 성장을 뒷받침하고 있습니다.

유육종증 치료제 시장의 주요 기업들은 치료 저항성 사례에 대응하고 질병 관리 결과를 개선하기 위해 항TNFα 단일클론항체 등 혁신적인 솔루션 개발에 주력하고 있습니다. 항TNFα 단일클론항체는 종양괴사인자 알파(TNFα)를 억제하여 유육종증 및 기타 자가면역질환의 염증과 조직 손상을 감소시키는 생물학적 제제입니다. 예를 들어, 2023년 11월 미국 제약사 센트리아(Xentria Inc.)는 유육종증 치료제 XTMAB-16에 대해 유럽의약품청(EMA)으로부터 희귀의약품 지정을 받았습니다. XTMAB-16은 유육종증의 특징인 육아종 형성에 관여하는 주요 염증 분자인 TNFα를 표적으로 억제하는 인간 마우스 키메라 단클론 항체입니다. 이 약은 이 염증 경로를 억제하여, 특히 폐에 영향을 미치는 폐육종증에서 육아종의 진행을 지연시킬 수 있는 가능성을 목표로 하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병(M&A)

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

A sarcoidosis drug is any medication used to manage the abnormal immune response and granuloma formation seen in sarcoidosis, a multisystem inflammatory disorder that most commonly affects the lungs and lymph nodes. These drugs aim to reduce symptoms and prevent organ damage.

The main types of sarcoidosis drugs include treatments for ocular sarcoidosis, neurosarcoidosis, cardiac sarcoidosis, musculoskeletal sarcoidosis, cutaneous sarcoidosis, renal sarcoidosis, hepatic sarcoidosis, sarcoidosis of the spleen and bone marrow, and pulmonary sarcoidosis. Ocular sarcoidosis refers specifically to eye inflammation caused by sarcoidosis, characterized by granuloma formation in eye tissues, which can lead to symptoms such as redness, pain, and vision loss. Treatment options include corticosteroids, immunosuppressants, antimalarials, and tumor necrosis factor-alpha (TNF-alpha) inhibitors. These medications are used for conditions affecting the lungs, skin, heart, and nervous system, and may be administered orally, intravenously, or topically. Key end users include hospitals, clinics, surgical centers, diagnostic centers, and other healthcare facilities.

Tariffs have impacted SNP genotyping by raising the cost of imported instruments, reagents, and microarrays used in genetic analysis workflows. These impacts have been particularly pronounced for research laboratories in emerging markets that rely heavily on international suppliers. Trade related frictions have caused delays in equipment procurement and extended project timelines for genomics research. Rising tariff related expenses have influenced budgeting, sourcing strategies, and adoption of advanced genotyping technologies. Positively, tariffs have encouraged regional manufacturing of genomic tools, localized reagent production, and stronger long term supply chain development.

The sarcoidosis drug market research report is one of a series of new reports from The Business Research Company that provides sarcoidosis drug market statistics, including sarcoidosis drug industry global market size, regional shares, competitors with a sarcoidosis drug market share, detailed sarcoidosis drug market segments, market trends and opportunities, and any further data you may need to thrive in the sarcoidosis drug industry. This sarcoidosis drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The sarcoidosis drug market size has grown strongly in recent years. It will grow from $7.88 billion in 2025 to $8.42 billion in 2026 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to advances in genomic research, declining sequencing costs, expansion of academic research, growth in diagnostic testing, pharmaceutical r&d investments.

The sarcoidosis drug market size is expected to see strong growth in the next few years. It will grow to $10.98 billion in 2030 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to personalized medicine adoption, growth in companion diagnostics, ai-enabled genomics, rising demand from pharma companies, government genomics initiatives. Major trends in the forecast period include expansion of precision medicine applications, rising use of cfdna and liquid biopsy, high-throughput genotyping technologies, integration with ai-based data analysis, growth in pharmacogenomics.

The growing number of clinical trials is expected to drive the growth of the sarcoidosis drug market in the coming years. Clinical trials are research studies conducted on humans to assess the safety, efficacy, and potential side effects of medical treatments or interventions. The rise in clinical trials is largely driven by the increasing demand for personalized and innovative therapies, which require thorough testing to ensure safety and effectiveness. Sarcoidosis drugs are evaluated in these trials to determine their impact on disease progression, safety profile, and therapeutic outcomes, aiming to identify more effective treatment options. For example, in December 2024, the Association of the British Pharmaceutical Industry, a UK-based pharmaceutical industry trade body, reported that the total number of industry-sponsored clinical trials initiated in the United Kingdom increased from 411 in 2022 to 426 in 2023, while Phase III trial initiations grew by 16.5% over the same period, rising from 182 to 212. Therefore, the increasing number of clinical trials is supporting the growth of the sarcoidosis drug market.

Major companies in the sarcoidosis drug market are focusing on developing innovative solutions, such as anti-TNFa monoclonal antibodies, to address treatment-resistant cases and improve disease management outcomes. Anti-TNFa monoclonal antibodies are biologic drugs that block tumor necrosis factor-alpha (TNFa) to reduce inflammation and tissue damage in sarcoidosis and other autoimmune conditions. For instance, in November 2023, Xentria Inc., a US-based pharmaceutical company, received orphan drug designation from the European Medicines Agency (EMA) for XTMAB-16 to treat sarcoidosis. XTMAB-16 is a chimeric human-murine monoclonal antibody that targets and blocks TNFa, a key inflammatory molecule involved in granuloma formation characteristic of sarcoidosis. The drug aims to disrupt this inflammatory pathway and potentially slow granuloma progression, particularly in pulmonary sarcoidosis, which affects the lungs.

In June 2023, Xentria Inc. collaborated with Meitheal Pharmaceuticals Inc. Through this partnership, Xentria aims to accelerate the development and commercialization of XTMAB-16, providing an effective, targeted treatment for pulmonary sarcoidosis and addressing a critical unmet medical need. Meitheal Pharmaceuticals Inc. is a US-based company specializing in the manufacture of sarcoidosis drugs.

Major companies operating in the sarcoidosis drug market are AbbVie Inc., Novartis AG., Viatris Inc., Boehringer Ingelheim International GmbH, Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Mallinckrodt plc, Kyorin Pharmaceutical Co. Ltd., Molecure S.A., aTyr Pharma Inc., Xentria Inc., Relief Therapeutics Holding AG, Foresee Pharmaceuticals Co. Ltd., OrphAI Therapeutics Inc., Bellus Health Inc., AI Therapeutics Inc., Araim Pharmaceuticals Inc., Kinevant Sciences GmbH, SarcoMed USA Inc.

North America was the largest region in the sarcoidosis drug market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sarcoidosis drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the sarcoidosis drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The sarcoidosis drug market consists of sales of hydroxychloroquine, leflunomide, and cyclophosphamide. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Sarcoidosis Drug Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses sarcoidosis drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for sarcoidosis drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The sarcoidosis drug market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Ocular Sarcoidosis; Neurosarcoidosis; Cardiac Sarcoidosis; Musculoskeletal Sarcoidosis; Cutaneous Sarcoidosis; Renal Sarcoidosis; Hepatic Sarcoidosis; Sarcoidosis Of The Spleen and Bone Marrow; Pulmonary Sarcoidosis
• 2) By Mechanism of Action: Corticosteroid; Immunosuppressants; Antimalarial; Tumor Necrosis Factor-alpha (TNF-Alpha) Inhibitors
• 3) By Indication: Lung Involvement; Skin Involvement; Cardiac Involvement; Neurological Involvement
• 4) By Route of Administration: Oral; Intravenous; Topical
• 5) By End User: Hospitals And Clinics; Surgical Centers; Diagnostic Centers; Other End Users
• Subsegments:
• 1) By Ocular Sarcoidosis: Anterior uveitis; Posterior uveitis; Panuveitis; Conjunctival sarcoidosis
• 2) By Neurosarcoidosis: Cranial neuropathy; Meningeal involvement; Spinal cord sarcoidosis; Peripheral neuropathy
• 3) By Cardiac Sarcoidosis: Arrhythmias; Heart block; Cardiomyopathy; Heart failure
• 4) By Musculoskeletal Sarcoidosis: Arthropathy; Myopathy; Bone lesions; Sarcoid arthritis
• 5) By Cutaneous Sarcoidosis: Lupus pernio; Erythema nodosum; Maculopapular lesions; Scar sarcoidosis
• 6) By Renal Sarcoidosis: Granulomatous interstitial nephritis; Nephrocalcinosis; Hypercalciuria; Tubulointerstitial nephritis
• 7) By Hepatic Sarcoidosis: Granulomatous hepatitis; Hepatomegaly; Cholestasis; Portal hypertension
• 8) By Sarcoidosis Of The Spleen And Bone Marrow: Splenomegaly; Hypersplenism; Bone marrow infiltration; Pancytopenia
• 9) By Pulmonary Sarcoidosis: Hilar lymphadenopathy; Interstitial lung disease; Fibrotic sarcoidosis; Bronchial obstruction
• Companies Mentioned: AbbVie Inc.; Novartis AG.; Viatris Inc.; Boehringer Ingelheim International GmbH; Aurobindo Pharma Limited; Hikma Pharmaceuticals PLC; Lupin Limited; Mallinckrodt plc; Kyorin Pharmaceutical Co. Ltd.; Molecure S.A.; aTyr Pharma Inc.; Xentria Inc.; Relief Therapeutics Holding AG; Foresee Pharmaceuticals Co. Ltd.; OrphAI Therapeutics Inc.; Bellus Health Inc.; AI Therapeutics Inc.; Araim Pharmaceuticals Inc.; Kinevant Sciences GmbH; SarcoMed USA Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Sarcoidosis Drug Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Sarcoidosis Drug Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Sarcoidosis Drug Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Sarcoidosis Drug Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Internet of Things (IoT), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Expansion Of Precision Medicine Applications
  • 4.2.2 Rising Use Of cfDNA And Liquid Biopsy
  • 4.2.3 High-Throughput Genotyping Technologies
  • 4.2.4 Integration With AI-Based Data Analysis
  • 4.2.5 Growth In Pharmacogenomics

5. Sarcoidosis Drug Market Analysis Of End Use Industries

• 5.1 Hospitals And Clinics
• 5.2 Research Laboratories
• 5.3 Diagnostic Laboratories
• 5.4 Pharmaceutical And Biotechnological Companies
• 5.5 Academic And Government Institutions

6. Sarcoidosis Drug Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Sarcoidosis Drug Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Sarcoidosis Drug PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Sarcoidosis Drug Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Sarcoidosis Drug Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Sarcoidosis Drug Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Sarcoidosis Drug Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Sarcoidosis Drug Market Segmentation

• 9.1. Global Sarcoidosis Drug Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Ocular Sarcoidosis, Neurosarcoidosis, Cardiac Sarcoidosis, Musculoskeletal Sarcoidosis, Cutaneous Sarcoidosis, Renal Sarcoidosis, Hepatic Sarcoidosis, Sarcoidosis Of The Spleen and Bone Marrow, Pulmonary Sarcoidosis
• 9.2. Global Sarcoidosis Drug Market, Segmentation By Mechanism of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Corticosteroid, Immunosuppressants, Antimalarial, Tumor Necrosis Factor-alpha (TNF-Alpha) Inhibitors
• 9.3. Global Sarcoidosis Drug Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Lung Involvement, Skin Involvement, Cardiac Involvement, Neurological Involvement
• 9.4. Global Sarcoidosis Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oral, Intravenous, Topical
• 9.5. Global Sarcoidosis Drug Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals And Clinics, Surgical Centers, Diagnostic Centers, Other End Users
• 9.6. Global Sarcoidosis Drug Market, Sub-Segmentation Of Ocular Sarcoidosis, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Anterior uveitis, Posterior uveitis, Panuveitis, Conjunctival sarcoidosis
• 9.7. Global Sarcoidosis Drug Market, Sub-Segmentation Of Neurosarcoidosis, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Cranial neuropathy, Meningeal involvement, Spinal cord sarcoidosis, Peripheral neuropathy
• 9.8. Global Sarcoidosis Drug Market, Sub-Segmentation Of Cardiac Sarcoidosis, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Arrhythmias, Heart block, Cardiomyopathy, Heart failure
• 9.9. Global Sarcoidosis Drug Market, Sub-Segmentation Of Musculoskeletal Sarcoidosis, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Arthropathy, Myopathy, Bone lesions, Sarcoid arthritis
• 9.10. Global Sarcoidosis Drug Market, Sub-Segmentation Of Cutaneous Sarcoidosis, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Lupus pernio, Erythema nodosum, Maculopapular lesions, Scar sarcoidosis
• 9.11. Global Sarcoidosis Drug Market, Sub-Segmentation Of Renal Sarcoidosis, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Granulomatous interstitial nephritis, Nephrocalcinosis, Hypercalciuria, Tubulointerstitial nephritis
• 9.12. Global Sarcoidosis Drug Market, Sub-Segmentation Of Hepatic Sarcoidosis, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Granulomatous hepatitis, Hepatomegaly, Cholestasis, Portal hypertension
• 9.13. Global Sarcoidosis Drug Market, Sub-Segmentation Of Sarcoidosis Of The Spleen And Bone Marrow, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Splenomegaly, Hypersplenism, Bone marrow infiltration, Pancytopenia
• 9.14. Global Sarcoidosis Drug Market, Sub-Segmentation Of Pulmonary Sarcoidosis, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hilar lymphadenopathy, Interstitial lung disease, Fibrotic sarcoidosis, Bronchial obstruction

10. Sarcoidosis Drug Market Regional And Country Analysis

• 10.1. Global Sarcoidosis Drug Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Sarcoidosis Drug Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Sarcoidosis Drug Market

• 11.1. Asia-Pacific Sarcoidosis Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Sarcoidosis Drug Market, Segmentation By Type, Segmentation By Mechanism of Action, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Sarcoidosis Drug Market

• 12.1. China Sarcoidosis Drug Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Sarcoidosis Drug Market, Segmentation By Type, Segmentation By Mechanism of Action, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Sarcoidosis Drug Market

• 13.1. India Sarcoidosis Drug Market, Segmentation By Type, Segmentation By Mechanism of Action, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Sarcoidosis Drug Market

• 14.1. Japan Sarcoidosis Drug Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Sarcoidosis Drug Market, Segmentation By Type, Segmentation By Mechanism of Action, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Sarcoidosis Drug Market

• 15.1. Australia Sarcoidosis Drug Market, Segmentation By Type, Segmentation By Mechanism of Action, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Sarcoidosis Drug Market

• 16.1. Indonesia Sarcoidosis Drug Market, Segmentation By Type, Segmentation By Mechanism of Action, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Sarcoidosis Drug Market

• 17.1. South Korea Sarcoidosis Drug Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Sarcoidosis Drug Market, Segmentation By Type, Segmentation By Mechanism of Action, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Sarcoidosis Drug Market

• 18.1. Taiwan Sarcoidosis Drug Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Sarcoidosis Drug Market, Segmentation By Type, Segmentation By Mechanism of Action, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Sarcoidosis Drug Market

• 19.1. South East Asia Sarcoidosis Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Sarcoidosis Drug Market, Segmentation By Type, Segmentation By Mechanism of Action, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Sarcoidosis Drug Market

• 20.1. Western Europe Sarcoidosis Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Sarcoidosis Drug Market, Segmentation By Type, Segmentation By Mechanism of Action, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Sarcoidosis Drug Market

• 21.1. UK Sarcoidosis Drug Market, Segmentation By Type, Segmentation By Mechanism of Action, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Sarcoidosis Drug Market

• 22.1. Germany Sarcoidosis Drug Market, Segmentation By Type, Segmentation By Mechanism of Action, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Sarcoidosis Drug Market

• 23.1. France Sarcoidosis Drug Market, Segmentation By Type, Segmentation By Mechanism of Action, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Sarcoidosis Drug Market

• 24.1. Italy Sarcoidosis Drug Market, Segmentation By Type, Segmentation By Mechanism of Action, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Sarcoidosis Drug Market

• 25.1. Spain Sarcoidosis Drug Market, Segmentation By Type, Segmentation By Mechanism of Action, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Sarcoidosis Drug Market

• 26.1. Eastern Europe Sarcoidosis Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Sarcoidosis Drug Market, Segmentation By Type, Segmentation By Mechanism of Action, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Sarcoidosis Drug Market

• 27.1. Russia Sarcoidosis Drug Market, Segmentation By Type, Segmentation By Mechanism of Action, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Sarcoidosis Drug Market

• 28.1. North America Sarcoidosis Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Sarcoidosis Drug Market, Segmentation By Type, Segmentation By Mechanism of Action, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Sarcoidosis Drug Market

• 29.1. USA Sarcoidosis Drug Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Sarcoidosis Drug Market, Segmentation By Type, Segmentation By Mechanism of Action, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Sarcoidosis Drug Market

• 30.1. Canada Sarcoidosis Drug Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Sarcoidosis Drug Market, Segmentation By Type, Segmentation By Mechanism of Action, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Sarcoidosis Drug Market

• 31.1. South America Sarcoidosis Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Sarcoidosis Drug Market, Segmentation By Type, Segmentation By Mechanism of Action, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Sarcoidosis Drug Market

• 32.1. Brazil Sarcoidosis Drug Market, Segmentation By Type, Segmentation By Mechanism of Action, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Sarcoidosis Drug Market

• 33.1. Middle East Sarcoidosis Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Sarcoidosis Drug Market, Segmentation By Type, Segmentation By Mechanism of Action, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Sarcoidosis Drug Market

• 34.1. Africa Sarcoidosis Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Sarcoidosis Drug Market, Segmentation By Type, Segmentation By Mechanism of Action, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Sarcoidosis Drug Market Regulatory and Investment Landscape

36. Sarcoidosis Drug Market Competitive Landscape And Company Profiles

• 36.1. Sarcoidosis Drug Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Sarcoidosis Drug Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Sarcoidosis Drug Market Company Profiles
  • 36.3.1. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Novartis AG. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Viatris Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Boehringer Ingelheim International GmbH Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Aurobindo Pharma Limited Overview, Products and Services, Strategy and Financial Analysis

37. Sarcoidosis Drug Market Other Major And Innovative Companies

• Hikma Pharmaceuticals PLC, Lupin Limited, Mallinckrodt plc, Kyorin Pharmaceutical Co. Ltd., Molecure S.A., aTyr Pharma Inc., Xentria Inc., Relief Therapeutics Holding AG, Foresee Pharmaceuticals Co. Ltd., OrphAI Therapeutics Inc., Bellus Health Inc., AI Therapeutics Inc., Araim Pharmaceuticals Inc., Kinevant Sciences GmbH, SarcoMed USA Inc.

38. Global Sarcoidosis Drug Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Sarcoidosis Drug Market

40. Sarcoidosis Drug Market High Potential Countries, Segments and Strategies

• 40.1 Sarcoidosis Drug Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Sarcoidosis Drug Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Sarcoidosis Drug Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer